forvisirvat

Forvisirvat is a first-in-class, orally administered **epigenetic sirtuin 6 (SIRT6) activator** developed primarily for the treatment of **major depressive disorder (MDD)**, with additional clinical development for schizophrenia. SIRT6 is an enzyme implicated in the regulation of DNA repair, mitochondrial function, inflammation, and glucose homeostasis, biological processes believed to be involved in depression and other neuropsychiatric and possibly neurodegenerative diseases. Forvisirvat’s mechanism is distinct from traditional antidepressants, acting as an activator of SIRT6 and thus modulating these pathways through an epigenetic effect. Preclinical and clinical studies have demonstrated the drug’s ability to enhance neural activity tied to mood regulation and cognition. Notably, clinical results highlight greater efficacy in female MDD patients, and the drug has shown a favorable safety profile in clinical trials[1][2][3][4][5][7][8].